Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial

By sjmartinez • October 15, 2024

Chew KW, McGinley B, Moser C, Li JZ, Evering TH, Ritz J, Javan AC, Margolis D, Wohl DA, Hughes MD, Daar ES, Currier JS, Eron JJ, Smith DM; ACTIV-2/A5401 Study Team. Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial. J Infect Dis. 2024 Oct 14:jiae501. doi: 10.1093/infdis/jiae501. Epub ahead of print. PMID: 39400063.

Tags: covid-19, COVID-19 treatment, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, non-hospitalized adults, Publications, SARS-CoV-2, symptom rebound, viral rebound

Do measures of general versus pregnancy-related anxiety have distinct maternal-fetal-placental biology?

Duberstein ZT, Murphy H, Wu Q, Meng Y, Wang C, Smith R, Salafia C, Chowdhury SF, Barrett E, Scheible K, Qiu X, O'Connor TG. Do[...]

Differential Performance of Polygenic Score for Coronary Artery Disease Based on Coronary Artery Calcium Between Men Living With and Without HIV

Wojcik G, Arvanitis M, Haberlen S, Kim EY, Kim H, Nam K, Feinstein MJ, Wolinsky S, Margolick JB, Budoff M, Magnani JW, Duggal P, Post[...]

Enhancing accuracy and adherence in blood pressure monitoring in living kidney donation: implementing technologies to overcome challenges

Tantisattamo E, Rattanasompattikul M, Traitanon O, Eguchi N, Ichii H, Kantachuvesiri S, Kalantar-Zadeh K. Enhancing accuracy and adherence in blood pressure monitoring in living kidney[...]